RT Journal Article
SR Electronic
T1 Large-scale screening of asymptomatic for SARS-CoV-2 variants of concern and rapid P.1 takeover, Curitiba, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.18.21258649
DO 10.1101/2021.06.18.21258649
A1 Douglas Adamoski
A1 Jaqueline Carvalho de Oliveira
A1 Ana Claudia Bonatto
A1 Roseli Wassem
A1 Meri Bordignon Nogueira
A1 Sonia Mara Raboni
A1 Edvaldo da Silva Trindade
A1 Emanuel Maltempi Souza
A1 SCB-UFPR COVID-19 team
A1 Daniela Fiori Gradia
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.18.21258649.abstract
AB To provide a safer environment for individuals working on-site at the Federal University of Paraná, Curitiba, Brazil, we performed a large-scale mass testing SARS-CoV-2 program coupled with variant genotyping using two PCR-based approaches. We observed a fast dominance of the Gamma variant, displacing other variants in less than three months.Article Summary Line Coronavirus variants of concern may use asymptomatic population as silent spreaders to perform a fast displacement of previous established strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the: PROPLAN /Federal University of Parana, Curitiba-Parana- Brazil; FINEP - Funder of Studies and Projects, Ministry of Science, Technology and Innovation- Brazil - Institutional Network Project: Laboratories for Diagnostic tests for COVID-19 (0494/20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical Committee Boarding of the Complexo Hospital de Clinicas of Universidade Federal do Parana approved this study (CAAE: 31687620.2.0000.0096).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request